Trial reportNature medicine2018
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.
3 registry-linked trialsAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 493 papers.
0numbers the graph read from it
0cells of the map it votes in
493citing papers in PubMed
39.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT03658785 phase1 / phase2recruitingnot on this mapstarted 2020, after this paper: background citation
Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Solid Tumor
A Phase I Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Neoantigen-expanded Autologous Immune Cell Therapy for Solid Tumors
NCT06224049 early_phase1unknown statusnot on this mapstarted 2023, after this paper: background citation
A Clinical Study to Evaluate the Safety, Tolerability and Initial Efficacy of Targeted Haploidentical Neoantigen T Cell Injection (hNeo-T) in the Treatment of Relapsed or Refractory EBV-positive T-cell Lymphoma
Who cites it
493 citing papers in PubMed, 763 citations in OpenAlex.
- Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial.Nature medicine · 2025Trial
- LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma.Oncoimmunology · 2024Trial
- Receptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen.Signal transduction and targeted therapy · 2026Article
- The DNA damage response and cancer immunotherapy.Nature reviews. Cancer · 2026Review
- Adoptive cell therapy in lung cancer: progress, challenges, and prospects.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Structural basis for T-cell receptor recognition of p53Acta crystallographica. Section D, Structural biology · 2026Article
- Harnessing immunity against breast cancer: from checkpoints to cell therapies.Journal of translational medicine · 2026Review
- Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal transduction and targeted therapy · 2026Review
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
- Spleen-targeted neoantigen mRNA vaccine induces ISG15Cell reports. Medicine · 2026Article
- Review
- Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response.Journal for immunotherapy of cancer · 2026Article
- Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes Leads to a Dominant Exhausted T-cell Population with a Lack of Memory Markers.Cancer immunology research · 2026Article
- Tumor-Infiltrating Natural Killer Cell Characterization in Pancreatic Ductal Adenocarcinoma.Cells · 2026Article
- Article
- Advances in Breast Cancer Research: Immunological, Pathological, and Pharmacological Perspectives for Improving Patient Outcomes.International journal of molecular sciences · 2026Review
- Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges.Cancer immunology, immunotherapy : CII · 2026Review
- Clinical Trials Update in Resectable Esophageal Cancer.Cancers · 2026Review
- T cell immunotherapy for solid tumors: limitations, progress, and future prospects.Frontiers in immunology · 2026Review
- Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review.Breast cancer (Dove Medical Press) · 2026Review
433 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors at 2 institutions in 1 country.
Nikolaos ZacharakisSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Harshini ChinnasamySurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mary BlackSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hui XuSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Yong-Chen LuSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-0275-9825
Zhili ZhengSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Anna PasettoSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Michelle LanghanSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Thomas SheltonSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Todd PrickettSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jared GartnerSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Li JiaSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Katarzyna Trebska-McGowanDepartment of Surgery, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Robert P SomervilleSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Paul F RobbinsSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Steven A RosenbergSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. sar@mail.nih.gov.
Stephanie L GoffSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Steven A FeldmanSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
National Institutes of Health · USVirginia Commonwealth University · US
Funding
Adoptive Cell Transfer Immunotherapy of CancerZIABC010984 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROSENBERG, STEVEN · 2009 to 2025
$56.8MDNA Sequencing and FACS Core FacilitiesZICBC010948 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROBBINS, PAUL · 2009 to 2025
$35.6MCell Production Core FacilityZICBC011569 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HALAS, HYUNMI · 2014 to 2025
$17.4MAdoptive Cell Transfer Immunotherapy of CancerZ01BC010984 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROSENBERG, STEVEN · 2008 to 2008
$1.5MIntramural NIH HHS Z01 BC010984
Abstract
Immunotherapy using either checkpoint blockade or the adoptive transfer of antitumor lymphocytes has shown effectiveness in treating cancers with high levels of somatic mutations-such as melanoma, smoking-induced lung cancers and bladder cancer-with little effect in other common epithelial cancers that have lower mutation rates, such as those arising in the gastrointestinal tract, breast and ovary
Indexed as
Adoptive TransferBreast NeoplasmsFemaleFusion Regulatory Protein 1, Heavy ChainHumansLymphocytes, Tumor-InfiltratingMiddle AgedMutationNeoplasm MetastasisProteasome Endopeptidase ComplexRemission InductionECPAS protein, humanFusion Regulatory Protein 1, Heavy ChainProteasome Endopeptidase ComplexSLC3A2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.